![](https://news.europawire.eu/wp-content/uploads/2013/11/merck.jpg)
• The ESPART* Phase III clinical study focuses on patients that respond poorly to attempts at ovarian stimulation • Study aims to recruit 946 patients across 17 European countries Darmstadt, Germany, 28-3-2014 — /EuropaWire/ — Merck, the global pharmaceutical and chemical company, … Read the full press release